Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trial
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: We aimed to define an optimal target population and drug-specific biomarkers that may predict dipeptidyl peptidase (DPP)-4 inhibitor responses in non-alcoholic fatty liver disease (NAFLD). Methods: An exploration study (study I) was performed using three different NAFLD models (basket study design; high-fat diet [HFD], methionine choline-deficient diet [MCD], and high-cholesterol Western diet [WD] models). RNA transcriptome analysis was performed on pre-studied liver tissues to identify biomarkers that could predict the response to DPP-4 inhibitors. In the validation study (study II), the HFD-induced NAFLD model was divided into high and low hepatic insulin-like growth factor binding protein 1 (Igfbp-1) groups based on the pre-study liver biopsy. Results: DPP-4 inhibitor attenuated the NAFLD activity score and fibrosis stage in the HFD model but not in the WD and MCD models. The overall response rate was 19% across the modified basket NAFLD trial and 42%, 25%, and 0% in the HFD, WD, and MCD models. Hepatic Igfbp-1 expression was higher in the responder group than in the non-responder group in pre-study biopsy samples. In contrast, hepatic Igfbp-1 expression was lower in the responder group than in the non-responder group in the end-study biopsy samples. DPP-4 inhibitor response rates were 83% and 17% in the baseline hepatic high Igfbp-1 and low Igfbp-1 groups, respectively. Hepatic messenger RNA Igfbp-1 expression was positively correlated with serum IGFBP-1 levels. Conclusions: The DPP-4 inhibitor response was higher in the HFD phenotype and pre-treatment levels of hepatic or serum IGFBP-1 were high.
Abstract
Background/Aims: We aimed to define an optimal target population and drug-specific biomarkers that may predict dipeptidyl peptidase (DPP)-4 inhibitor responses in non-alcoholic fatty liver disease (NAFLD). Methods: An exploration study (study I) was performed using three different NAFLD models (basket study design; high-fat diet [HFD], methionine choline-deficient diet [MCD], and high-cholesterol Western diet [WD] models). RNA transcriptome analysis was performed on pre-studied liver tissues to identify biomarkers that could predict the response to DPP-4 inhibitors. In the validation study (study II), the HFD-induced NAFLD model was divided into high and low hepatic insulin-like growth factor binding protein 1 (Igfbp-1) groups based on the pre-study liver biopsy. Results: DPP-4 inhibitor attenuated the NAFLD activity score and fibrosis stage in the HFD model but not in the WD and MCD models. The overall response rate was 19% across the modified basket NAFLD trial and 42%, 25%, and 0% in the HFD, WD, and MCD models. Hepatic Igfbp-1 expression was higher in the responder group than in the non-responder group in pre-study biopsy samples. In contrast, hepatic Igfbp-1 expression was lower in the responder group than in the non-responder group in the end-study biopsy samples. DPP-4 inhibitor response rates were 83% and 17% in the baseline hepatic high Igfbp-1 and low Igfbp-1 groups, respectively. Hepatic messenger RNA Igfbp-1 expression was positively correlated with serum IGFBP-1 levels. Conclusions: The DPP-4 inhibitor response was higher in the HFD phenotype and pre-treatment levels of hepatic or serum IGFBP-1 were high.
참고문헌 (27)
- Li J, "Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019 : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 4, pp.389~398 (2019)
- Younossi ZM, "The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe", Hepatology, 64, pp.1577~1586 (2016)
- Connolly JJ, "Future pharmacotherapy for nonalcoholic steatohepatitis(NASH) : review of phase 2 and 3 trials", J Clin Transl Hepatol, 6, pp.264~275 (2018)
- Friedman SL, "Mechanisms of NAFLD development and therapeutic strategies", Nat Med, 24, pp.908~922 (2018)
- Eslam M, "Genetic insights for drug development in NAFLD", Trends Pharmacol Sci, 40, pp.506~516 (2019)
- Harrison SA, "Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH : results from randomized phase III STELLAR trials", J Hepatol, 73, pp.26~39 (2020)
- Younossi ZM, "Obeticholic acid for the treatment of nonalcoholic steatohepatitis : interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial", Lancet, 394, pp.2184~2196 (2019)
- Park JJH, "Systematic review of basket trials, umbrella trials, and platform trials : a landscape analysis of master protocols", Trials, 20, pp.572~ (2019)
- Dharmalingam M, "Nonalcoholic fatty liver disease and type 2 diabetes mellitus", Indian J Endocrinol Metab, 22, pp.421~428 (2018)
- Tomah S, "Nonalcoholic fatty liver disease and type 2 diabetes : where do diabetologists stand?", Clin Diabetes Endocrinol, 6, pp.9~ (2020)
- Mentzel S, "Organ distribution of aminopeptidase A and dipeptidyl peptidase IV in normal mice", J Histochem Cytochem, 44, pp.445~461 (1996)
- Barchetta I, "Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD", NASH in individuals with and without obesity and metabolic disease, 2021, pp.44, 979~988
- Nakamura K, "A long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, as a preventive drug for the development of hepatic steatosis in high-fructose diet-fed ob", ob mice, 2017, pp.39, 969~983
- 김미경, "Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models", Archives of Pharmacal Research, 40(2), pp.268~281 (2017), 대한약학회
- Alam S, "Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients : a 1-year randomized control trial", Hepat Med, 10, pp.23~31 (2018)
- 채연지, "Feasibility and Stability of Liver Biopsy before Treatment for Preclinical Nonalcoholic Fatty Liver Studies", Journal of Korean Medical Science, 34(2), pp.1~11 (2019), 대한의학회
- Donthamsetty S, "Nonalcoholic fatty liver sensitizes rats to carbon tetrachloride hepatotoxicity", Hepatology, 45, pp.391~403 (2007)
- Ueki K, "Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse", Proc Natl Acad Sci U S A, 101, pp.10422~10427 (2004)
- Siu LL, "Next-generation sequencing to guide clinical trials", Clin Cancer Res, 21, pp.4536~4544 (2015)
- Doostparast Torshizi A, "Next-generation sequencing in drug development : target identification and genetically stratified clinical trials", Drug Discov Today, 23, pp.1776~1783 (2018)
- Snyder HS, "Non-alcoholic fatty liver disease : a review of anti-diabetic pharmacologic therapies", J Clin Transl Hepatol, 6, pp.168~174 (2018)
- Macauley M, "Effect of vildagliptin on hepatic steatosis", J Clin Endocrinol Metab, 100, pp.1578~1585 (2015)
- Cui J, "Sitagliptin vs. placebo for non-alcoholic fatty liver disease : a randomized controlled trial", J Hepatol, 65, pp.369~376 (2016)
- Deng XL, "Short article : a randomizedcontrolled study of sitagliptin for treating diabetes mellitus complicated by nonalcoholic fatty liver disease", Eur J Gastroenterol Hepatol, 29, pp.297~301 (2017)
- Yan J, "Liraglutide, sitagliptin, and insulin glargine added to metformin : the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease", Hepatology, 69, pp.2414~2426 (2019)
- Lewitt MS, "Insulin-like growth factor-binding protein-1 in the prediction and development of type 2 diabetes in middle-aged Swedish men", Diabetologia, 51, pp.1135~1145 (2008)
- Stanley TL, "Relationship of IGF-1 and IGF-binding proteins to disease severity and glycemia in nonalcoholic fatty liver disease", J Clin Endocrinol Metab, 106, pp.e520~e533 (2021)